ERCC1 expression in diffuse large b-cell lymphoma patients treated with a cisplatin-based regimen : a brief communication
There is growing interest in defining biomarkers that could predict response to different chemotherapeutic agents. Excision repair cross complement 1 (ERCC1) enzyme has been shown to predict benefit of cisplatin in different types of cancer. As cisplatin-based regimens are frequently used in the sal...
Gespeichert in:
| Veröffentlicht in: | Journal of Egyptian National Cancer Institute 2007-09, Vol.19 (3), p.176-177 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 177 |
|---|---|
| container_issue | 3 |
| container_start_page | 176 |
| container_title | Journal of Egyptian National Cancer Institute |
| container_volume | 19 |
| creator | Martinellli, Giovanni Steffanoni, Sarah Raviele, Paola R. Pruneri, Giancarlo Azim, Hatim A. Peccatori, Fedro A. |
| description | There is growing interest in defining biomarkers that
could predict response to different chemotherapeutic
agents. Excision repair cross complement 1 (ERCC1)
enzyme has been shown to predict benefit of cisplatin in
different types of cancer. As cisplatin-based regimens are
frequently used in the salvage treatment of diffuse large
B-cell lymphomas (DLBCL), a small pilot study was
conducted to determine whether ERCC1 is expressed in
this disease or not. Out of seven patients examined, only
one had a 25% ERCC1 expression, which could represent
a tumour truly expressing this marker. However, expression
was not able to predict response to treatment. It remains
unclear whether ERCC1 could serve as a predictive marker
for cisplatin in this disease requiring further studies. |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_733919710</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>733919710</sourcerecordid><originalsourceid>FETCH-LOGICAL-e760-37527d5f39a7989e902097cbc181419699e14f69017a094814ae02aaa3809b733</originalsourceid><addsrcrecordid>eNo9kF9LwzAUxYsobk6_gUjefAok7Zb0-iZl_oGBIHsvt-3tFmnSmrTovr2RTZ_u4ZwfF845S-ZS5ZoDgDqPWkrBRabSWXIVwocQSgm9ukxmEiQIBWKeHNbvRSEZfQ-eQjC9Y8axxrTtFIh16HfEKl5T17HuYId9b5ENOBpyY2CjJxypYV9m3DNktQlDFzPHKwzR9rQzlhx7iFnlDbWs7q2dnKkj1Lvr5KLFLtDN6S6S7dN6W7zwzdvza_G44aSV4JlepbpZtRmghhwIRCpA11Utc7mUoABILttYRWoUsIwmkkgRMcsFVDrLFsn98e3g-8-JwlhaE34LoaN-CmVE4hhaikjencipstSUgzcW_aH8GysCt0eAok8t_hNpDrnIfgCT22_T</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>733919710</pqid></control><display><type>article</type><title>ERCC1 expression in diffuse large b-cell lymphoma patients treated with a cisplatin-based regimen : a brief communication</title><source>EZB-FREE-00999 freely available EZB journals</source><creator>Martinellli, Giovanni ; Steffanoni, Sarah ; Raviele, Paola R. ; Pruneri, Giancarlo ; Azim, Hatim A. ; Peccatori, Fedro A.</creator><creatorcontrib>Martinellli, Giovanni ; Steffanoni, Sarah ; Raviele, Paola R. ; Pruneri, Giancarlo ; Azim, Hatim A. ; Peccatori, Fedro A.</creatorcontrib><description>There is growing interest in defining biomarkers that
could predict response to different chemotherapeutic
agents. Excision repair cross complement 1 (ERCC1)
enzyme has been shown to predict benefit of cisplatin in
different types of cancer. As cisplatin-based regimens are
frequently used in the salvage treatment of diffuse large
B-cell lymphomas (DLBCL), a small pilot study was
conducted to determine whether ERCC1 is expressed in
this disease or not. Out of seven patients examined, only
one had a 25% ERCC1 expression, which could represent
a tumour truly expressing this marker. However, expression
was not able to predict response to treatment. It remains
unclear whether ERCC1 could serve as a predictive marker
for cisplatin in this disease requiring further studies.</description><identifier>ISSN: 1110-0362</identifier><identifier>EISSN: 1687-9996</identifier><identifier>PMID: 19190690</identifier><language>eng</language><publisher>Cairo, Egypt: Cairo University, National Cancer Institute</publisher><subject>Lymphomas ; الأورام</subject><ispartof>Journal of Egyptian National Cancer Institute, 2007-09, Vol.19 (3), p.176-177</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/19190690$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Martinellli, Giovanni</creatorcontrib><creatorcontrib>Steffanoni, Sarah</creatorcontrib><creatorcontrib>Raviele, Paola R.</creatorcontrib><creatorcontrib>Pruneri, Giancarlo</creatorcontrib><creatorcontrib>Azim, Hatim A.</creatorcontrib><creatorcontrib>Peccatori, Fedro A.</creatorcontrib><title>ERCC1 expression in diffuse large b-cell lymphoma patients treated with a cisplatin-based regimen : a brief communication</title><title>Journal of Egyptian National Cancer Institute</title><addtitle>J Egypt Natl Canc Inst</addtitle><description>There is growing interest in defining biomarkers that
could predict response to different chemotherapeutic
agents. Excision repair cross complement 1 (ERCC1)
enzyme has been shown to predict benefit of cisplatin in
different types of cancer. As cisplatin-based regimens are
frequently used in the salvage treatment of diffuse large
B-cell lymphomas (DLBCL), a small pilot study was
conducted to determine whether ERCC1 is expressed in
this disease or not. Out of seven patients examined, only
one had a 25% ERCC1 expression, which could represent
a tumour truly expressing this marker. However, expression
was not able to predict response to treatment. It remains
unclear whether ERCC1 could serve as a predictive marker
for cisplatin in this disease requiring further studies.</description><subject>Lymphomas</subject><subject>الأورام</subject><issn>1110-0362</issn><issn>1687-9996</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2007</creationdate><recordtype>article</recordtype><recordid>eNo9kF9LwzAUxYsobk6_gUjefAok7Zb0-iZl_oGBIHsvt-3tFmnSmrTovr2RTZ_u4ZwfF845S-ZS5ZoDgDqPWkrBRabSWXIVwocQSgm9ukxmEiQIBWKeHNbvRSEZfQ-eQjC9Y8axxrTtFIh16HfEKl5T17HuYId9b5ENOBpyY2CjJxypYV9m3DNktQlDFzPHKwzR9rQzlhx7iFnlDbWs7q2dnKkj1Lvr5KLFLtDN6S6S7dN6W7zwzdvza_G44aSV4JlepbpZtRmghhwIRCpA11Utc7mUoABILttYRWoUsIwmkkgRMcsFVDrLFsn98e3g-8-JwlhaE34LoaN-CmVE4hhaikjencipstSUgzcW_aH8GysCt0eAok8t_hNpDrnIfgCT22_T</recordid><startdate>200709</startdate><enddate>200709</enddate><creator>Martinellli, Giovanni</creator><creator>Steffanoni, Sarah</creator><creator>Raviele, Paola R.</creator><creator>Pruneri, Giancarlo</creator><creator>Azim, Hatim A.</creator><creator>Peccatori, Fedro A.</creator><general>Cairo University, National Cancer Institute</general><scope>ADJCN</scope><scope>AHFXO</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>200709</creationdate><title>ERCC1 expression in diffuse large b-cell lymphoma patients treated with a cisplatin-based regimen : a brief communication</title><author>Martinellli, Giovanni ; Steffanoni, Sarah ; Raviele, Paola R. ; Pruneri, Giancarlo ; Azim, Hatim A. ; Peccatori, Fedro A.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-e760-37527d5f39a7989e902097cbc181419699e14f69017a094814ae02aaa3809b733</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2007</creationdate><topic>Lymphomas</topic><topic>الأورام</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Martinellli, Giovanni</creatorcontrib><creatorcontrib>Steffanoni, Sarah</creatorcontrib><creatorcontrib>Raviele, Paola R.</creatorcontrib><creatorcontrib>Pruneri, Giancarlo</creatorcontrib><creatorcontrib>Azim, Hatim A.</creatorcontrib><creatorcontrib>Peccatori, Fedro A.</creatorcontrib><collection>الدوريات العلمية والإحصائية - e-Marefa Academic and Statistical Periodicals</collection><collection>معرفة - المحتوى العربي الأكاديمي المتكامل - e-Marefa Academic Complete</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of Egyptian National Cancer Institute</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Martinellli, Giovanni</au><au>Steffanoni, Sarah</au><au>Raviele, Paola R.</au><au>Pruneri, Giancarlo</au><au>Azim, Hatim A.</au><au>Peccatori, Fedro A.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>ERCC1 expression in diffuse large b-cell lymphoma patients treated with a cisplatin-based regimen : a brief communication</atitle><jtitle>Journal of Egyptian National Cancer Institute</jtitle><addtitle>J Egypt Natl Canc Inst</addtitle><date>2007-09</date><risdate>2007</risdate><volume>19</volume><issue>3</issue><spage>176</spage><epage>177</epage><pages>176-177</pages><issn>1110-0362</issn><eissn>1687-9996</eissn><abstract>There is growing interest in defining biomarkers that
could predict response to different chemotherapeutic
agents. Excision repair cross complement 1 (ERCC1)
enzyme has been shown to predict benefit of cisplatin in
different types of cancer. As cisplatin-based regimens are
frequently used in the salvage treatment of diffuse large
B-cell lymphomas (DLBCL), a small pilot study was
conducted to determine whether ERCC1 is expressed in
this disease or not. Out of seven patients examined, only
one had a 25% ERCC1 expression, which could represent
a tumour truly expressing this marker. However, expression
was not able to predict response to treatment. It remains
unclear whether ERCC1 could serve as a predictive marker
for cisplatin in this disease requiring further studies.</abstract><cop>Cairo, Egypt</cop><pub>Cairo University, National Cancer Institute</pub><pmid>19190690</pmid><tpages>2</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1110-0362 |
| ispartof | Journal of Egyptian National Cancer Institute, 2007-09, Vol.19 (3), p.176-177 |
| issn | 1110-0362 1687-9996 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_733919710 |
| source | EZB-FREE-00999 freely available EZB journals |
| subjects | Lymphomas الأورام |
| title | ERCC1 expression in diffuse large b-cell lymphoma patients treated with a cisplatin-based regimen : a brief communication |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-22T05%3A55%3A55IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=ERCC1%20expression%20in%20diffuse%20large%20b-cell%20lymphoma%20patients%20treated%20with%20a%20cisplatin-based%20regimen%20:%20a%20brief%20communication&rft.jtitle=Journal%20of%20Egyptian%20National%20Cancer%20Institute&rft.au=Martinellli,%20Giovanni&rft.date=2007-09&rft.volume=19&rft.issue=3&rft.spage=176&rft.epage=177&rft.pages=176-177&rft.issn=1110-0362&rft.eissn=1687-9996&rft_id=info:doi/&rft_dat=%3Cproquest_pubme%3E733919710%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=733919710&rft_id=info:pmid/19190690&rfr_iscdi=true |